. Author manuscript; available in PMC: 2012 Oct 1.

Published in final edited form as: Lifetime Data Anal. 2011 Jun 26;17(4):566–593. doi: 10.1007/s10985-011-9199-8

Table 5.

Simulation Results for comparing treatment ZDV monotherapy and ZDV + ddI (5000 Monte-Carlo samples, true β = 80:13, entries in parentheses for SE and Monte-Carlo SE are relative efficiencies with respect to ${\hat{β}}_{1}$

Statistics	n	t-test	${\hat{β}}_{1}$	${\hat{β}}_{2}$	${\hat{β}}_{3}$
Bias	250	−21.050	−5.953	−5.564	−3.871
	600	−21.120	−5.258	−4.980	−3.533
	1054	−21.310	−5.267	−5.027	−3.664
AveSE	250	62.645 (0.71)	52.961 (1.00)	51.637 (1.05)	47.126 (1.26)
	600	40.858 (0.70)	34.246 (1.00)	33.572 (1.04)	30.815 (1.24)
	1054	30.949 (0.70)	25.859 (1.00)	25.395 (1.04)	23.357 (1.23)
MCSE	250	64.104 (0.60)	49.756 (1.00)	50.074 (0.99)	49.070 (1.03)
	600	41.377 (0.59)	31.891 (1.00)	31.490 (1.03)	30.952 (1.06)
	1054	31.492 (0.59)	24.150 (1.00)	23.866 (1.02)	23.530 (1.05)
95% CI	250	94.3	96.9	96.2	94.9
	600	91.9	96.4	96.1	94.9
	1054	89.2	95.7	96.0	94.5